Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Open Access
- 10 June 2015
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (1), 56-66
- https://doi.org/10.1002/jcph.566
Abstract
Ceftolozane/tazobactam is an antipseudomonal antibacterial approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) and in phase 3 clinical development for treatment of nosocomial pneumonia. A population pharmacokinetic (PK) model with the plasma-to-epithelial lining fluid (ELF) kinetics of ceftolozane/tazobactam was used to justify dosing regimens for patients with nosocomial pneumonia in phase 3 studies. Monte Carlo simulations were performed to determine ceftolozane/tazobactam dosing regimens with a >90% probability of target attainment (PTA) for a range of pharmacokinetic/pharmacodynamic targets at relevant minimum inhibitory concentrations (MICs) for key pathogens in nosocomial pneumonia. With a plasma-to-ELF penetration ratio of approximately 50%, as observed from an ELF PK study, a doubling of the current dose regimens for different renal functions that are approved for cUTIs and cIAIs is needed to achieve >90% PTA for nosocomial pneumonia. For example, a 3-g dose of ceftolozane/tazobactam for nosocomial pneumonia patients with normal renal function is needed to achieve a >90% PTA (actual 98%) for the 1-log kill target against pathogens with an MIC of ≤8 mg/L in ELF, compared with the 1.5-g dose approved for cIAIs and cUTIs.Keywords
Funding Information
- Merck and Co., Inc.
This publication has 37 references indexed in Scilit:
- Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation StudyAntimicrobial Agents and Chemotherapy, 2013
- How should we dose antibiotics for pneumonia in the ICU?Current Opinion in Infectious Diseases, 2013
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending DosesAntimicrobial Agents and Chemotherapy, 2012
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase InhibitorsAntimicrobial Agents and Chemotherapy, 2012
- Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining FluidClinical Pharmacokinetics, 2011
- Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated PneumoniaAntimicrobial Agents and Chemotherapy, 2011
- Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumoniaEuropean Respiratory Journal, 2010
- Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia*Critical Care Medicine, 2008
- Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Intermittent bolus dosing of ceftazidime in critically ill patientsJournal of Antimicrobial Chemotherapy, 1997